GF40738260
Ruthenium
Ruthenium, foil, 6x6mm, thickness 1.0mm, 99.9%
Synonym(s):
Ruthenium, RU000220
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Recommended Products
Assay
99.9%
form
foil
manufacturer/tradename
Goodfellow 407-382-60
resistivity
7.1 μΩ-cm, 0°C
bp
3900 °C (lit.)
mp
2310 °C (lit.)
density
12.45 g/cm3 (lit.)
SMILES string
[Ru]
InChI
1S/Ru
InChI key
KJTLSVCANCCWHF-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class Code
13 - Non Combustible Solids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Nitric oxide : biology and chemistry, 26(1), 38-53 (2011-12-20)
Nitric oxide plays an important role in various biological processes, such as neurotransmission, blood pressure control, immunological responses, and antioxidant action. The control of its local concentration, which is crucial for obtaining the desired effect, can be achieved with exogenous
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service